Clearmind Medicine To Implement 1-for-40 Reverse Stock Split Next Week

Clearmind Medicine announced a 1-for-40 reverse share split effective Dec. 15, 2025 to regain compliance with Nasdaq’s minimum bid price rule, cutting outstanding shares from about 59.99 million to roughly 1.5 million, rounding up fractional shares and proportionately adjusting options and warrants. The clinical-stage biotech is advancing CMND-100 (MEAI), an oral Phase I/IIa candidate for alcohol use disorder that has dosed its first participant at Hadassah Medical Centre and produced positive early top-line data with the DSMB recommending continuation; additional psychedelic-derived programs are in preclinical stages for binge behaviors, depression and metabolic disorders. The stock has traded between $0.10 and $2.18 over the past year, closed yesterday at $0.114 (down 6.08%) and was trading around $0.08 premarket (down ~23%), underscoring market pressure ahead of the corporate action.

Analysis

Clearmind Medicine announced a 1-for-40 reverse share split effective December 15, 2025, reducing issued and outstanding common shares from approximately 59.99 million to roughly 1.50 million, with no fractional shares issued and fractional holdings rounded up; outstanding options and warrants will be adjusted proportionately. Management framed the move as necessary to regain compliance with the Nasdaq Minimum Bid Price Rule, making the split a regulatory remediation rather than a value-creation transaction.

The market reaction has been negative and volatile: the stock has traded between $0.10 and $2.18 over the past year, closed yesterday at $0.114 (down 6.08%) and was trading about $0.08 premarket (down ~23%), consistent with the provided moderately negative sentiment score. A reverse split of this magnitude typically compresses float, can reduce liquidity, and often triggers short-term selling pressure despite reducing the share count.

Clearmind’s primary fundamental driver remains CMND-100 (MEAI), an oral Phase I/IIa candidate for alcohol use disorder that recently dosed its first participant at Hadassah Medical Centre and produced early top-line results that prompted the DSMB to recommend continuation; additional psychedelic-derived programs remain in preclinical stages. The clinical readouts and subsequent DSMB assessments are the most material near-term catalysts to offset technical and liquidity risks associated with the split, whereas regulatory compliance and potential financing needs represent principal downside risks.

Key Decisions for Investors

• Defer initiating meaningful new long positions until post-split trading liquidity stabilizes and Nasdaq compliance is confirmed, given the premarket drop to ~$0.08 and elevated volatility
• Monitor Phase I/IIa CMND-100 readouts and future DSMB statements closely and consider adding exposure only after clear, positive efficacy or safety signals that materially change fundamentals
• Reduce position size or hedge existing exposure ahead of the December 15 reverse split to manage the risk of exaggerated price swings from a tighter float and rounding effects
• Track the adjusted terms for options and warrants and any near-term financing communications, as these could introduce dilution or further downward pressure on the post-split share price